321 related articles for article (PubMed ID: 26309161)
1. The oncoprotein HBXIP promotes glucose metabolism reprogramming via downregulating SCO2 and PDHA1 in breast cancer.
Liu F; Zhang W; You X; Liu Y; Li Y; Wang Z; Wang Y; Zhang X; Ye L
Oncotarget; 2015 Sep; 6(29):27199-213. PubMed ID: 26309161
[TBL] [Abstract][Full Text] [Related]
2. The oncoprotein HBXIP promotes human breast cancer growth through down-regulating p53 via miR-18b/MDM2 and pAKT/MDM2 pathways.
Li H; Wang Z; Jiang M; Fang RP; Shi H; Shen Y; Cai XL; Liu Q; Ye K; Fan SJ; Zhang WY; Ye LH
Acta Pharmacol Sin; 2018 Nov; 39(11):1787-1796. PubMed ID: 30181579
[TBL] [Abstract][Full Text] [Related]
3. The oncoprotein HBXIP suppresses gluconeogenesis through modulating PCK1 to enhance the growth of hepatoma cells.
Shi H; Fang R; Li Y; Li L; Zhang W; Wang H; Chen F; Zhang S; Zhang X; Ye L
Cancer Lett; 2016 Nov; 382(2):147-156. PubMed ID: 27609066
[TBL] [Abstract][Full Text] [Related]
4. The oncoprotein HBXIP enhances angiogenesis and growth of breast cancer through modulating FGF8 and VEGF.
Liu F; You X; Wang Y; Liu Q; Liu Y; Zhang S; Chen L; Zhang X; Ye L
Carcinogenesis; 2014 May; 35(5):1144-53. PubMed ID: 24464787
[TBL] [Abstract][Full Text] [Related]
5. Oncoprotein HBXIP Modulates Abnormal Lipid Metabolism and Growth of Breast Cancer Cells by Activating the LXRs/SREBP-1c/FAS Signaling Cascade.
Zhao Y; Li H; Zhang Y; Li L; Fang R; Li Y; Liu Q; Zhang W; Qiu L; Liu F; Zhang X; Ye L
Cancer Res; 2016 Aug; 76(16):4696-707. PubMed ID: 26980761
[TBL] [Abstract][Full Text] [Related]
6. The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer.
Li H; Liu Q; Wang Z; Fang R; Shen Y; Cai X; Gao Y; Li Y; Zhang X; Ye L
J Biol Chem; 2015 Sep; 290(37):22649-61. PubMed ID: 26229107
[TBL] [Abstract][Full Text] [Related]
7. HBXIP drives metabolic reprogramming in hepatocellular carcinoma cells via METTL3-mediated m6A modification of HIF-1α.
Yang N; Wang T; Li Q; Han F; Wang Z; Zhu R; Zhou J
J Cell Physiol; 2021 May; 236(5):3863-3880. PubMed ID: 33305825
[TBL] [Abstract][Full Text] [Related]
8. Oncoprotein HBXIP induces PKM2 via transcription factor E2F1 to promote cell proliferation in ER-positive breast cancer.
Liu BW; Wang TJ; Li LL; Zhang L; Liu YX; Feng JY; Wu Y; Xu FF; Zhang QS; Bao MZ; Zhang WY; Ye LH
Acta Pharmacol Sin; 2019 Apr; 40(4):530-538. PubMed ID: 29925919
[TBL] [Abstract][Full Text] [Related]
9. The oncoprotein HBXIP upregulates Lin28B via activating TF II D to promote proliferation of breast cancer cells.
Liu Q; Bai X; Li H; Zhang Y; Zhao Y; Zhang X; Ye L
Int J Cancer; 2013 Sep; 133(6):1310-22. PubMed ID: 23494474
[TBL] [Abstract][Full Text] [Related]
10. The oncoprotein HBXIP activates transcriptional coregulatory protein LMO4 via Sp1 to promote proliferation of breast cancer cells.
Yue L; Li L; Liu F; Hu N; Zhang W; Bai X; Li Y; Zhang Y; Fu L; Zhang X; Ye L
Carcinogenesis; 2013 Apr; 34(4):927-35. PubMed ID: 23291272
[TBL] [Abstract][Full Text] [Related]
11. miR-520b regulates migration of breast cancer cells by targeting hepatitis B X-interacting protein and interleukin-8.
Hu N; Zhang J; Cui W; Kong G; Zhang S; Yue L; Bai X; Zhang Z; Zhang W; Zhang X; Ye L
J Biol Chem; 2011 Apr; 286(15):13714-22. PubMed ID: 21343296
[TBL] [Abstract][Full Text] [Related]
12. SIRT3 elicited an anti-Warburg effect through HIF1α/PDK1/PDHA1 to inhibit cholangiocarcinoma tumorigenesis.
Xu L; Li Y; Zhou L; Dorfman RG; Liu L; Cai R; Jiang C; Tang D; Wang Y; Zou X; Wang L; Zhang M
Cancer Med; 2019 May; 8(5):2380-2391. PubMed ID: 30993888
[TBL] [Abstract][Full Text] [Related]
13. The oncoprotein HBXIP enhances migration of breast cancer cells through increasing filopodia formation involving MEKK2/ERK1/2/Capn4 signaling.
Li Y; Zhang Z; Zhou X; Li L; Liu Q; Wang Z; Bai X; Zhao Y; Shi H; Zhang X; Ye L
Cancer Lett; 2014 Dec; 355(2):288-96. PubMed ID: 25304384
[TBL] [Abstract][Full Text] [Related]
14. The oncoprotein HBXIP competitively binds KEAP1 to activate NRF2 and enhance breast cancer cell growth and metastasis.
Zhou XL; Zhu CY; Wu ZG; Guo X; Zou W
Oncogene; 2019 May; 38(21):4028-4046. PubMed ID: 30692632
[TBL] [Abstract][Full Text] [Related]
15. The oncoprotein HBXIP up-regulates SCG3 through modulating E2F1 and miR-509-3p in hepatoma cells.
Wang Y; Cui M; Cai X; Sun B; Liu F; Zhang X; Ye L
Cancer Lett; 2014 Oct; 352(2):169-78. PubMed ID: 24882622
[TBL] [Abstract][Full Text] [Related]
16. The oncoprotein HBXIP up-regulates YAP through activation of transcription factor c-Myb to promote growth of liver cancer.
Wang Y; Fang R; Cui M; Zhang W; Bai X; Wang H; Liu B; Zhang X; Ye L
Cancer Lett; 2017 Jan; 385():234-242. PubMed ID: 27765671
[TBL] [Abstract][Full Text] [Related]
17. HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g.
Cai X; Wang X; Cao C; Gao Y; Zhang S; Yang Z; Liu Y; Zhang X; Zhang W; Ye L
Cancer Lett; 2018 Feb; 415():11-19. PubMed ID: 29174803
[TBL] [Abstract][Full Text] [Related]
18. NRF2 facilitates breast cancer cell growth via HIF1ɑ-mediated metabolic reprogramming.
Zhang HS; Du GY; Zhang ZG; Zhou Z; Sun HL; Yu XY; Shi YT; Xiong DN; Li H; Huang YH
Int J Biochem Cell Biol; 2018 Feb; 95():85-92. PubMed ID: 29275212
[TBL] [Abstract][Full Text] [Related]
19. The oncoprotein HBXIP upregulates PDGFB via activating transcription factor Sp1 to promote the proliferation of breast cancer cells.
Zhang Y; Zhao Y; Li L; Shen Y; Cai X; Zhang X; Ye L
Biochem Biophys Res Commun; 2013 May; 434(2):305-10. PubMed ID: 23537647
[TBL] [Abstract][Full Text] [Related]
20. HBXIP up-regulates ACSL1 through activating transcriptional factor Sp1 in breast cancer.
Wang Y; Cai X; Zhang S; Cui M; Liu F; Sun B; Zhang W; Zhang X; Ye L
Biochem Biophys Res Commun; 2017 Mar; 484(3):565-571. PubMed ID: 28132807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
